Shapiro Haber & Urmy LLP Announces It Filed the Securities Fraud Class Action Lawsuit Against InVivo Therapeutics Holdings Corp. (NVIV)

BOSTON, Aug. 5, 2014

Shapiro Haber & Urmy LLP conducted a careful investigation before filing its Complaint, which alleges that the Defendants made false and misleading statements about the FDA's approval of a clinical trial and the time for completion of the trial and submission of data to the FDA. The Complaint alleges that these misstatements and omissions by Defendants misrepresented and/or omitted material facts to the investing public, in violation of Sections 10(b) and 20(a) of the Securities Exchange Act.

The class action is brought on behalf of all persons and entities who purchased common stock of InVivo from April 5, 2013 through August 26, 2013.

If you purchased shares of InVivo common stock during the above time period, you may move the court to appoint you as lead plaintiff no later than 60 days from today.

The factual and legal bases for the Plaintiff's claims are set forth in greater detail in the Complaint, which is available at www.shulaw.com or can be obtained, without any obligation, from counsel for the Plaintiff, Shapiro Haber & Urmy LLP. More information about the law firm and its qualifications is available at www.shulaw.com. If you would like more information about this case or you are interested in joining the suit, please contact the firm at the telephone numbers below or by email.

Several other law firms have published notices announcing the filing of a law suit against InVivo.
Shapiro Haber & Urmy LLP is the only firm that has investigated the company and has actually filed a complaint.